Stocks and Investing
Stocks and Investing
Mon, November 14, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Berens Maintained (AZN) at Buy with Increased Target to $79 on, Nov 14th, 2022
Andrew Berens of SVB Leerink, Maintained "AstraZeneca PLC" (AZN) at Buy with Increased Target from $78 to $79 on, Nov 14th, 2022.
Andrew has made no other calls on AZN in the last 4 months.
There is 1 other peer that has a rating on AZN. Out of the 1 peers that are also analyzing AZN, 0 agree with Andrew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Andrew
- John Eade of "Argus Research" Upgraded from Hold to Strong Buy and Held Target at $75 on, Monday, August 29th, 2022
Contributing Sources